Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
3.900
-0.090 (-2.26%)
Feb 20, 2026, 4:00 PM EST - Market closed
Cellectis Employees
As of December 31, 2024, Cellectis had 222 total employees, including 216 full-time and 6 part-time employees. The number of employees increased by 1 or 0.45% compared to the previous year.
Employees
222
Change (1Y)
1
Growth (1Y)
0.45%
Revenue / Employee
$371,851
Profits / Employee
-$159,248
Market Cap
293.12M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 222 | 1 | 0.45% | 216 | 6 |
| Dec 31, 2023 | 221 | -16 | -6.75% | 216 | 5 |
| Dec 31, 2022 | 237 | -63 | -21.00% | 231 | 6 |
| Dec 31, 2021 | 300 | 19 | 6.76% | 294 | 6 |
| Dec 31, 2020 | 281 | 17 | 6.44% | 272 | 9 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sutro Biopharma | 178 |
| Cabaletta Bio | 151 |
| Aura Biosciences | 109 |
| Armata Pharmaceuticals | 60 |
| ALX Oncology Holdings | 44 |
| Fennec Pharmaceuticals | 32 |
| Avalo Therapeutics | 23 |
| Relmada Therapeutics | 17 |
CLLS News
- 6 weeks ago - Monthly information on share capital and company voting rights - GlobeNewsWire
- 2 months ago - Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Benzinga
- 2 months ago - Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis - GlobeNewsWire
- 2 months ago - Cellectis Announces Arbitral Decision in Dispute with Servier - GlobeNewsWire
- 2 months ago - Cellectis' Allogeneic CAR-T Potential Still Justifies A 'Buy' - Seeking Alpha
- 2 months ago - ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL - GlobeNewsWire
- 3 months ago - Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells - GlobeNewsWire
- 3 months ago - Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire